ArticleEuropean journal of medical research2025
Brown adipose tissue activation and cardiovascular risk following PD-1 antibody therapy in cancer patients: a retrospective cohort study.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07538479 (NIVALIS Trial), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NIVALIS Trial: A Single-Center, Prospective, Single-Arm, Open-Label Phase I Exploratory Study Evaluating the Safety, Feasibility, and Preliminary Antitumor Activity of Controlled Cold Exposure Combined With PD-1/PD-L1 Immunotherapy in Patients With Solid Tumors
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThis study aimed to investigate whether PD-1 antibody therapy modulates brown adipose tissue (BAT) activity and whether BAT activation is associated with cardiovascular risk parameters in cancer patients. METHODS
designRetrospective cohort study.
settingTwo tertiary hospitals in Fujian Province, China (Fujian Provincial Hospital and Fujian Cancer Hospital), between January 2019 and January 2024.
participantsSixty-eight cancer patients (54 males, 14 females) who received PD-1 antibody therapy (e.g., pembrolizumab, 200 mg Q3W) and underwent paired EXCLUSION CRITERIA: hypothyroidism (n = 3), severe renal insufficiency (n = 2), and incomplete PET/CT or laboratory data. OUTCOME MEASURES: primary outcome: change in BAT activity (quantified by supraclavicular fossa SUVmax via PET/CT) pre- versus post-PD-1 therapy. SECONDARY OUTCOMES: changes in VAT/SAT SUVmax, lipid profiles (triglycerides [TG], total cholesterol [TC], LDL-C, and HDL-C), arterial stiffness index (ASI), cardiac biomarkers (cTnT and NT-proBNP), and thyroid function (TSH, FT3, FT4).
resultsFollowing immunotherapy, BAT SUV
conclusionsPD-1 antibodies enhance BAT activity in cancer patients, and higher BAT activity is associated with reduced arterial stiffness. PET/CT-derived BAT SUVmax may serve as a novel biomarker for cardiovascular risk stratification during PD-1 antibody therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.